



**Dr. Julio Rosenstock, MD**

*Director Dallas Diabetes and Endocrine Center at Medical City and Clinical Professor of Medicine,  
University of Texas Southwestern Medical School, Dallas, Texas, USA*

---

Julio Rosenstock, MD, received his medical degree from the University Of Costa Rica School of Medicine. He completed fellowships in Endocrinology and Diabetes at the Royal Postgraduate Medical School, Hammersmith Hospital in London and at the University of Texas Southwestern Medical Center in Dallas. He is board certified in internal medicine and in endocrinology and metabolism.

Dr. Rosenstock is the Director of the Dallas Diabetes and Endocrine Center at Medical City, an endocrine practice and clinical research facility. He is also a Clinical Professor of Medicine at the University of Texas Southwestern Medical Center at Dallas. He is a member of numerous professional societies and the former president of the Greater Dallas Chapter of the American Diabetes Association and the Texas Diabetes and Endocrine Association. He is actively involved in diabetes education and serves as the representative of The Endocrine Society to NDEP (National Diabetes Education Program sponsored by NIH and CDC) and is also the Chair of the Diabetes Task Force of the Hormone Foundation of The Endocrine Society.

His clinical and research activities have focused on exploring novel agents and therapeutic strategies to improve glycemic control. Over the last 25 years he has participated in hundreds of clinical trials for the development of new oral agents and insulin preparations.

Dr. Rosenstock's main interest has been early insulin intervention with combination strategies to reach glycemic targets in type 2 diabetes. He was involved in multiple clinical trials exploring the role of basal insulin analogs and different inhaled insulin preparations in diabetes management. Most recently, he has developed a special interest and has been actively involved in research development programs of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors as a clinical investigator and scientific advisor.

He is recognized as a key opinion leader in the field of diabetes management and has published extensively on exploring novel therapies to improve glycemic control. He has more than 250 publications, including peer-reviewed papers and numerous abstracts, and has also contributed to several clinics and book chapters on various topics in the field of diabetes. He is currently involved as an editorial board member of *Diabetes Care*, *Practical Diabetology*, *Cardiovascular Diabetology* and *Avances en Diabetologia* and is an active reviewer for several journals.

Dr. Rosenstock has chaired or been a featured speaker at multiple lectures and presentations both nationally and internationally.